101 related articles for article (PubMed ID: 9825249)
1. [Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupenthixol decanoate for a twelve month perioid].
Pach J; Finkbeiner T; Glaser T; Haug J; Osterheider M; Tegeler J
Fortschr Neurol Psychiatr; 1998 Oct; 66(10):442-9. PubMed ID: 9825249
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
[TBL] [Abstract][Full Text] [Related]
3. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
Philipp M; Lesch OM; Schmauss M; Dose M; Glaser T
Psychiatr Prax; 2003 May; 30 Suppl 2():S94-6. PubMed ID: 14509050
[TBL] [Abstract][Full Text] [Related]
4. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study.
Levin FR; Evans SM; Coomaraswammy S; Collins ED; Regent N; Kleber HD
Am J Drug Alcohol Abuse; 1998 Aug; 24(3):343-60. PubMed ID: 9741939
[TBL] [Abstract][Full Text] [Related]
5. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Kong DS; Yeo SH
Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
[TBL] [Abstract][Full Text] [Related]
6. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
8. Low-dose zotepine in the maintenance treatment of schizophrenia.
Fleischhacker WW; Stuppäck C; Barnas C; Unterweger B; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):61-3. PubMed ID: 2883685
[TBL] [Abstract][Full Text] [Related]
9. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
Henderson DC; Goff DC
J Clin Psychiatry; 1996 Sep; 57(9):395-7. PubMed ID: 9746446
[TBL] [Abstract][Full Text] [Related]
10. Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia.
Yamagami S; Soejima K
Drugs Exp Clin Res; 1989; 15(4):171-6. PubMed ID: 2570687
[TBL] [Abstract][Full Text] [Related]
11. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
Youssef HA
Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
[TBL] [Abstract][Full Text] [Related]
12. Response of negative symptoms of schizophrenia to neuroleptic treatment.
Serban G; Siegel S; Gaffney M
J Clin Psychiatry; 1992 Jul; 53(7):229-34. PubMed ID: 1639741
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial.
Tang WK; Ungvari GS
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):373-9. PubMed ID: 12691772
[TBL] [Abstract][Full Text] [Related]
14. [Incidence of the deficit form in refractory schizophrenia].
Samuelian JC
Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial of flupenthixol decanoate in chronic withdrawn schizophrenic patients.
Vichaiya V
J Med Assoc Thai; 1980 Apr; 63(4):205-9. PubMed ID: 6991627
[No Abstract] [Full Text] [Related]
16. Long-term treatment with flupentixol results of a post-marketing surveillance study.
Messer T; Glaser T; Landen H; Schmauss M
J Psychopharmacol; 2009 Sep; 23(7):805-13. PubMed ID: 18562418
[TBL] [Abstract][Full Text] [Related]
17. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
18. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
[TBL] [Abstract][Full Text] [Related]
19. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment.
Martyns-Yellowe IS
West Afr J Med; 1994; 13(4):200-3. PubMed ID: 7756183
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
